Physician profile
Rona Spector
NPI 1831449909
$16,223.88
in general payments reported to CMS, 2019-2025
10 companies · $33.10 in 2025
The $33.10 reported for 2025 was less than what a typical Thoracic Surgery (Cardiothoracic Vascular Surgery) provider received nationally (typical 2025 total: $796).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $248 · 2021: $18.72 · 2022: $9,013 · 2023: $1,811 · 2024: $5,101 · 2025: $33.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $2,526 · Travel and Lodging: $2,407 · Food and Beverage: $2,003 · Gift: $8.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $2,525.89 |
| Travel and Lodging | $2,406.87 |
| Food and Beverage | $2,002.87 |
| Gift | $8.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $15,510.06 | 2019-2024 | Da Vinci Surgical System |
| Davol INC. | $185.52 | 2022-2023 | Phasix Mesh |
| Pulmonx Corporation | $135.69 | 2019-2021 | |
| Mentor Worldwide LLC | $125.00 | 2023 | Artoura Breast Tissue Expander, Mentor Memorygel Resterilizable Gel Sizer |
| Galvanize Therapeutics, INC | $110.14 | 2024 | Aliya System |
| Merck Sharp & Dohme LLC | $54.60 | 2023-2025 | Keytruda |
| Ethicon US, LLC | $37.08 | 2023 | Echelon; Endopath, Enseal |
| W. L. Gore & Associates, INC. | $25.89 | 2023 | Gore Bio-A Tissue Reinforcement |
| Tela Bio, INC. | $22.32 | 2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Amgen INC. | $17.58 | 2023 | Lumakras |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rona Spector listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.